PROGYLUTON

This brand name is authorized in Ecuador, Israel, Mexico, Singapore, Spain.

Active ingredients

The drug PROGYLUTON contains a combination of these active pharmaceutical ingredients (APIs):

1	Estradiol UNII OKG364O896 - ESTRADIOL VALERATE
	Estradiol, is chemically and biologically identical to endogenous human estradiol. It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms. Oestrogens prevent bone loss following menopause or ovariectomy.
	Read more about Estradiol
2	Norgestrel UNII 3J8Q1747Z2 - NORGESTREL
	Read more about Norgestrel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PROGYLUTON Coated tablets	MPI, EU: SmPC	Marketing Authorisation Holder

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03AA06	Norgestrel and ethinylestradiol	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AA Progestogens and estrogens, fixed combinations
Discover more medicines within G03AA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	26.943-03-06
ES	Centro de información online de medicamentos de la AEMPS	53201
IL	מִשְׂרַד הַבְּרִיאוּת	121
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	82110
SG	Health Sciences Authority	04778P